Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
MerlinTrader Deep Dive Nauticus Robotics (Nasdaq: $KITT): Ocean Robotics, Reverse Split Risk and the 2026 Commercialization Test A full EN/IT deep dive on Nauticus Robotics, its autonomous subsea robotics platform, SeaTrepid integration, East Coast offshore activity, UAE expansion plan, financial…
Northern Dynasty Minerals is not a conventional “mine is coming online next year” story. It is not a producer, it has no operating mining revenue, and the Pebble Project is not currently a permitted development-ready asset. The stock is instead a high-volatility legal and regulatory optionality vehicle tied to one of the largest undeveloped copper-gold systems in North America. Pebble is big enough to keep attracting speculative attention, but controversial enough to have remained trapped for years between environmental opposition, federal permitting decisions, an EPA Clean Water Act veto, and a long chain of litigation.
Today’s ReSPECT readout removes one major clinical uncertainty from the CorMedix story. The next layer is execution: pre-NDA interaction with FDA, a targeted sNDA in the second half of 2026, DefenCath pricing after July 1, 2026, possible 2027 add-on improvement, and any favorable evolution in the policy/legal framework around TDAPA and dialysis-drug access.
POET Technologies has entered a much more delicate phase of its AI photonics story. The April 27, 2026 purchase-order update is materially negative because the company confirmed that all purchase orders received from Celestial AI have been cancelled after Marvell acquired Celestial. But the headline is also easy to oversimplify. Based on the wording available today, the stated issue is not product failure, failed qualification, or a public technical rejection of POET’s platform. The stated issue is confidentiality and disclosure discipline.
Simple contract math: if the full 14.4 MMCF annual Phase 1 volume is delivered at $285/MCF, the gross plant-gate helium revenue implied by the contract is about $4.1 million per year before operating costs, taxes, timing/ramp effects, CPI escalation, any year-three redetermination, and non-helium revenue streams. This is arithmetic from the disclosed price and volume, not formal company guidance.
Compass Therapeutics just changed shape. The April 27, 2026 COMPANION-002 update is not a clean failure, but it is not the clean survival win many biotech traders wanted either. Tovecimig plus paclitaxel delivered a highly statistically significant progression-free survival benefit in second-line biliary tract cancer, confirmed the previously announced objective-response-rate win, and created a plausible FDA discussion path. At the same time, the study did not meet the overall survival secondary endpoint in the intent-to-treat analysis. That single sentence is enough to reset the debate around $CMPX.
Cytokinetics has moved from a long, often frustrating development-stage narrative into one of the cleanest “now prove the launch” stories in cardiovascular biotech. The company’s first approved medicine, MYQORZO (aficamten), is approved in the United States, China and the European Union for adults with symptomatic obstructive hypertrophic cardiomyopathy, and the U.S. launch began in January 2026 with the REMS, specialty pharmacy network and patient-support system active at availability. That changes the way $CYTK should be analyzed. The old question was whether aficamten could reach the market. The new question is whether Cytokinetics can convert a differentiated label into durable prescriptions, reimbursement access, center adoption and eventually a self-sustaining specialty cardiology franchise.
Intellia Therapeutics has moved from a pre-readout binary setup into a post-data regulatory and commercial execution story. On April 27, 2026, the company reported positive topline results from HAELO, the global Phase 3 trial of lonvoguran ziclumeran, known as lonvo-z, in hereditary angioedema. The trial met its primary endpoint and all key secondary endpoints. The company also reported favorable safety and tolerability data, with no serious adverse events observed in the lonvo-z arm as of the February 10, 2026 data cutoff.
The cleanest way to read $ONCO today is this: the move is less about a traditional biotech catalyst and more about a microcap market repricing a pending reverse-merger-style pivot into AI-powered humanoid robotics. Onconetix entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC, and company communications point to closing in the second half of 2026, subject to shareholder approval, required regulatory approvals and other closing conditions.
The important news is not simply that the FDA has moved to accelerate selected psychedelic or psychedelic-adjacent programs for serious mental illness. The real stock-market story is that a beaten-down, highly emotional and thinly traded sector has suddenly received something it had been missing for years: a near-term regulatory frame.
The cannabis sector is back on trader radar because Washington finally gave the market something concrete to trade around. The Department of Justice placed FDA-approved marijuana products and qualifying state-licensed medical marijuana products into Schedule III, while also pointing to a new administrative hearing beginning June 29, 2026, on the broader marijuana rescheduling process.
Akanda Corp. is one of the clearest examples of how a powerful sector catalyst can ignite an extremely small, structurally fragile, low-float equity without necessarily changing the underlying business. The April 2026 rally was real as a market event, but it should not be misread as fundamental confirmation. The stock moved because federal cannabis reform returned to the front page, because Akanda had just completed a 1-for-4.5 reverse stock split, and because the post-split share structure made the name unusually sensitive to retail momentum, scanner activity and possible short-covering dynamics.
Intel has spent years as one of the market’s most painful semiconductor turnaround stories. The company lost technological prestige, watched AMD take share in CPUs, watched TSMC become the gold standard in advanced manufacturing, and watched Nvidia capture the center of the artificial intelligence investment cycle. For a long time, Intel was the stock people remembered more than the stock people wanted to own.
Three biotech microcaps are entering a critical stretch of 2026 with meaningful near-term events that could shift their fundamental narratives. MBRX is the highest-binary nano-cap in the group, with a pivotal AML trial unblinding imminent; CRBP is the best-capitalized of the three, with FDA-aligned randomized registrational trials and an ASCO presentation weeks away; NTHI is the smallest, with two simultaneous CNS catalysts approaching simultaneously in brain cancer.
Palvella Therapeutics is not the usual early-stage biotech story built around a distant scientific promise and a fragile balance sheet. The company is already past a major clinical readout in its lead indication, has a clearly defined regulatory path it wants to pursue in the second half of 2026, and now has a near-term medical-meeting catalyst that can refresh investor attention within the next thirty days. The key date is May 20, 2026, when Palvella is scheduled to present late-breaking results from the Phase 3 SELVA study in microcystic lymphatic malformations and the Phase 2 TOIVA study in cutaneous venous malformations at the International Society for the Study of Vascular Anomalies World Congress in Philadelphia.
Nasdaq: $CMPS FDA Priority Voucher Rolling NDA Review COMP360 / TRD Compass Pathways (Nasdaq: $CMPS): FDA Priority Voucher, Rolling NDA Review and the COMP360 Psychedelic Medicine Breakthrough Compass Pathways has moved from a post-Phase 3 psychedelic biotech story into a…
Executive summary
Vistagen Therapeutics is not a clean “good news” story. It is a post-collapse biotech story with one fresh positive regulatory event, one still-important Phase 3 catalyst, one recently failed Phase 3 trial, a compressed valuation, a formal liquidity warning in its SEC filing, a Nasdaq minimum bid issue, and a retail base trying to decide whether the stock is a fallen angel or a value trap.
Intellia Therapeutics is entering one of the most important moments in its public-company history. On April 24, 2026, the company announced that it will report topline clinical data from the global Phase 3 HAELO trial of lonvoguran ziclumeran, also known as lonvo-z, in hereditary angioedema on Monday, April 27, 2026, with a webcast scheduled for 8:00 a.m. ET. Intellia describes this as the world’s first Phase 3 readout for an in vivo CRISPR gene-editing candidate. That phrase matters because NTLA is not simply reporting another late-stage biotech trial. The company is attempting to prove that a one-time in vivo CRISPR therapy can move from elegant science and early clinical promise into a pivotal dataset capable of supporting a regulatory filing.
What defined last week
The S&P 500 and Nasdaq closed at record highs, powered by a powerful semiconductor rally and renewed confidence that AI infrastructure spending is still translating into real earnings momentum.
Why LIDR is suddenly interesting again
AEye Inc. has re-entered the trader conversation because three ingredients arrived at the same time: fresh analyst attention, a clean technology narrative and unusually strong retail interest around a small-cap ticker. Craig-Hallum initiated coverage with a Buy rating and a $3.50 price target on April 24, 2026, giving the market a simple headline to trade. AEye also has a near-term event on the calendar, with first-quarter 2026 results scheduled for May 13, 2026 after the close, followed by a conference call and webcast.